Hyundai Chinese Medicine Group (01643) announced interim results with loss attributable to company owners of 25.9 million yuan year-on-year profit to loss

According to the Zhitong Finance App, Modern Chinese Medicine Group (01643) announced its 2026 interim results, with revenue of about 118.5 million yuan, an increase of about 82.9% over the previous year. The gross profit was 22.1 million yuan, an increase of about 36.4% over the previous year. The owner of the company should have accounted for a loss of 25.9 million yuan, a year-on-year profit to loss; a loss of 3.6 points per share.

According to the announcement, the increase in revenue was mainly due to increased orders from Chinese dealers in Hong Kong and mainland China. The loss was mainly due to increased promotion and marketing expenses and R&D costs, which were used to support the Group's expansion in China and enhance product quality and clinical value, respectively. Both expenses were aimed at promoting the Group's long-term development.